355 related articles for article (PubMed ID: 23832667)
21. c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.
Otte A; Rauprich F; von der Ohe J; Yang Y; Kommoss F; Feuerhake F; Hillemanns P; Hass R
Oncotarget; 2015 Oct; 6(31):31640-58. PubMed ID: 26436697
[TBL] [Abstract][Full Text] [Related]
22. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
Wu YM; Liu CH; Hu RH; Huang MJ; Lee JJ; Chen CH; Huang J; Lai HS; Lee PH; Hsu WM; Huang HC; Huang MC
Cancer Res; 2011 Dec; 71(23):7270-9. PubMed ID: 21990321
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells.
Salvi A; Sabelli C; Moncini S; Venturin M; Arici B; Riva P; Portolani N; Giulini SM; De Petro G; Barlati S
FEBS J; 2009 Jun; 276(11):2966-82. PubMed ID: 19490101
[TBL] [Abstract][Full Text] [Related]
24. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.
Ke AW; Shi GM; Zhou J; Wu FZ; Ding ZB; Hu MY; Xu Y; Song ZJ; Wang ZJ; Wu JC; Bai DS; Li JC; Liu KD; Fan J
Hepatology; 2009 Feb; 49(2):491-503. PubMed ID: 19065669
[TBL] [Abstract][Full Text] [Related]
25. Upregulation of the putative oncogene COTE1 contributes to human hepatocarcinogenesis through modulation of WWOX signaling.
Zhang H; Tian Y; Shen J; Wang Y; Xu Y; Wang Y; Han Z; Li X
Int J Oncol; 2014 Aug; 45(2):719-31. PubMed ID: 24899407
[TBL] [Abstract][Full Text] [Related]
26. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
27. RNA interference-mediated silencing of Stat5 induces apoptosis and growth suppression of hepatocellular carcinoma cells.
Zhang L; Zhao Z; Feng Z; Yin N; Lu G; Shan B
Neoplasma; 2012; 59(3):302-9. PubMed ID: 22296499
[TBL] [Abstract][Full Text] [Related]
28. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.
Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E
Hepatology; 1997 Apr; 25(4):862-6. PubMed ID: 9096589
[TBL] [Abstract][Full Text] [Related]
29. PKC mediates fluctuant ERK-paxillin signaling for hepatocyte growth factor-induced migration of hepatoma cell HepG2.
Hu CT; Cheng CC; Pan SM; Wu JR; Wu WS
Cell Signal; 2013 Jun; 25(6):1457-67. PubMed ID: 23524339
[TBL] [Abstract][Full Text] [Related]
30. Survivin-mediated cancer cell migration through GRP78 and epithelial-mesenchymal transition (EMT) marker expression in Mahlavu cells.
Tai CJ; Chin-Sheng H; Kuo LJ; Wei PL; Lu HH; Chen HA; Liu TZ; Liu JJ; Liu DZ; Ho YS; Wu CH; Chang YJ
Ann Surg Oncol; 2012 Jan; 19(1):336-43. PubMed ID: 21516372
[TBL] [Abstract][Full Text] [Related]
31. MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met.
Korhan P; Erdal E; Atabey N
Biochem Biophys Res Commun; 2014 Aug; 450(4):1304-12. PubMed ID: 25058462
[TBL] [Abstract][Full Text] [Related]
32. Up-regulation of C1GALT1 promotes breast cancer cell growth through MUC1-C signaling pathway.
Chou CH; Huang MJ; Chen CH; Shyu MK; Huang J; Hung JS; Huang CS; Huang MC
Oncotarget; 2015 Mar; 6(8):6123-35. PubMed ID: 25762620
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway.
Yang X; Zhang XF; Lu X; Jia HL; Liang L; Dong QZ; Ye QH; Qin LX
Hepatology; 2014 May; 59(5):1874-85. PubMed ID: 24259426
[TBL] [Abstract][Full Text] [Related]
34. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.
Fornari F; Milazzo M; Chieco P; Negrini M; Calin GA; Grazi GL; Pollutri D; Croce CM; Bolondi L; Gramantieri L
Cancer Res; 2010 Jun; 70(12):5184-93. PubMed ID: 20501828
[TBL] [Abstract][Full Text] [Related]
35. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
[TBL] [Abstract][Full Text] [Related]
36. CYP1A2 suppresses hepatocellular carcinoma through antagonizing HGF/MET signaling.
Yu J; Xia X; Dong Y; Gong Z; Li G; Chen GG; Lai PBS
Theranostics; 2021; 11(5):2123-2136. PubMed ID: 33500715
[No Abstract] [Full Text] [Related]
37. MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients.
Wang RY; Chen L; Chen HY; Hu L; Li L; Sun HY; Jiang F; Zhao J; Liu GM; Tang J; Chen CY; Yang YC; Chang YX; Liu H; Zhang J; Yang Y; Huang G; Shen F; Wu MC; Zhou WP; Wang HY
Gastroenterology; 2013 Dec; 145(6):1436-48.e1-12. PubMed ID: 23933603
[TBL] [Abstract][Full Text] [Related]
38. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.
Hiscox S; Jordan NJ; Jiang W; Harper M; McClelland R; Smith C; Nicholson RI
Endocr Relat Cancer; 2006 Dec; 13(4):1085-99. PubMed ID: 17158755
[TBL] [Abstract][Full Text] [Related]
39. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor.
Neaud V; Faouzi S; Guirouilh J; Le Bail B; Balabaud C; Bioulac-Sage P; Rosenbaum J
Hepatology; 1997 Dec; 26(6):1458-66. PubMed ID: 9397985
[TBL] [Abstract][Full Text] [Related]
40. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo.
Zhang SZ; Pan FY; Xu JF; Yuan J; Guo SY; Dai G; Xue B; Shen WG; Wen CJ; Zhao DH; Li CJ
Mol Cancer Ther; 2005 Oct; 4(10):1577-84. PubMed ID: 16227408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
